Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эксенатид – патофизиологически обоснованная терапия сахарного диабета типа 2
Эксенатид – патофизиологически обоснованная терапия сахарного диабета типа 2
Мкртумян А.М., Подачина С.В., Свиридова М.И. Эксенатид – патофизиологически обоснованная терапия сахарного диабета типа 2. Consilium Medicum. 2013; 15 (4): 20–23.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Мкртумян А.М., Оранская А.Н. Диабетическая макроангиопатия. В кн: Избранные лекции по эндокринологии. Под ред. А.С.Аметова. М.: МИА, 2009; с. 39–57.
2. DCCT: The Diabetes Control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
3. UKPDS: United Kingdom Prospective Diabetes Study Group Intensive blood-glucose control with sulphonureas or insulin and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
4. Turner RS, Cull CA, Frighi V, Holman RR. The UK Prospective Diabetes Study Group: glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
JAMA 1999; 281: 2005–12.
5. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9: 3265–345.
6. Anderson JW, Kendoll CW, Jenkins DJ et al. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331–9.
7. Nauck MA, Homberger E, Siegel EG. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492–8.
8. Garber AJ. Glucagon-Like peptide-1 – based therapies: new developments and emerging data. Obesity Metabol 2008; 10 (Suppl. 3): 22–35.
9. Мкртумян А.М. Баета – патофизиологический подход в лечении сахарного диабета типа 2. Эффективная фармакотерапия в эндокринологии. 2007; 3: 24–9.
10. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852–8.
11. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135–48.
12. Takei I, Kasatani T. Future therapy of diabetes mellitus. Biomedicine & Pharmacotherapy 2004; 58: 578–81.
13. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–40.
14. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005; 143 (8): 559–69.
15. D’Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882–E890.
16. Drucker DJ. Biological action and therapeutic potenctial of the glucagon-like peptides. Gastroenterology 2002; 122: 531–44.
17. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration exentid-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072–E1079.
18. Aronoff SL, Berkowitz K, Shreiner B et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004; 17: 183–90.
19. Holst JJ. Treatment of type 2 diabetes mellitus based on glucagons-like peptide-1. Expert Opin Investig Drugs 1999; 8 (9): 1409–15.
20. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852–8.
21. Kolterman OG, Buse JB, Fineman MS et al. Syntetic exentid-4 (exenatide) significantly redues postprandial and fasting plazma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–9.
22. De Fronzo RA et al. Diabetes Care 2005; 28: 1092–100.
23. Kendall DM et al. Diabetes Care 2005; 28: 1083–91.
2. DCCT: The Diabetes Control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
3. UKPDS: United Kingdom Prospective Diabetes Study Group Intensive blood-glucose control with sulphonureas or insulin and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
4. Turner RS, Cull CA, Frighi V, Holman RR. The UK Prospective Diabetes Study Group: glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
JAMA 1999; 281: 2005–12.
5. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9: 3265–345.
6. Anderson JW, Kendoll CW, Jenkins DJ et al. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331–9.
7. Nauck MA, Homberger E, Siegel EG. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492–8.
8. Garber AJ. Glucagon-Like peptide-1 – based therapies: new developments and emerging data. Obesity Metabol 2008; 10 (Suppl. 3): 22–35.
9. Мкртумян А.М. Баета – патофизиологический подход в лечении сахарного диабета типа 2. Эффективная фармакотерапия в эндокринологии. 2007; 3: 24–9.
10. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852–8.
11. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135–48.
12. Takei I, Kasatani T. Future therapy of diabetes mellitus. Biomedicine & Pharmacotherapy 2004; 58: 578–81.
13. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–40.
14. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005; 143 (8): 559–69.
15. D’Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882–E890.
16. Drucker DJ. Biological action and therapeutic potenctial of the glucagon-like peptides. Gastroenterology 2002; 122: 531–44.
17. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration exentid-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072–E1079.
18. Aronoff SL, Berkowitz K, Shreiner B et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004; 17: 183–90.
19. Holst JJ. Treatment of type 2 diabetes mellitus based on glucagons-like peptide-1. Expert Opin Investig Drugs 1999; 8 (9): 1409–15.
20. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852–8.
21. Kolterman OG, Buse JB, Fineman MS et al. Syntetic exentid-4 (exenatide) significantly redues postprandial and fasting plazma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–9.
22. De Fronzo RA et al. Diabetes Care 2005; 28: 1092–100.
23. Kendall DM et al. Diabetes Care 2005; 28: 1083–91.
Авторы
А.М.Мкртумян, С.В.Подачина, М.И.Свиридова
Кафедра эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ
Кафедра эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.